[ad_1]
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) has published details of a discovery that has potential applications in shrinking tumors across multiple cancer pathways. These findings could pave the way for effective treatment of small cell lung cancer, metastatic melanoma, and glioblastoma. The company’s stock rose sharply after the announcement.
These details were shared by the scientific founder of Ocean Biomedical Jack Elias in a presentation given at the Legorreta Cancer Center. These include novel therapeutic discoveries demonstrating the efficacy of monospecific and bispecific antibodies against Chitinase 3-like-1 (CHI3L1) and PD-1 as therapies for non-small cell lung cancer and glioblastoma multiforme.
Phase I trial
The Rhode Island-headquartered company has made significant progress in the development and progression of lung cancer, particularly the role of CHI3L1, a pro-tumor secreted protein associated with signaling pathways in cancer development.. Now, they are preparing to move their antibody therapy discovery into phase-1 clinical trials. It is important because it has the potential to treat people affected not only by lung metastases and melanoma but also non-small cell lung cancer, glioblastoma, and other forms of cancer.
Ocean Biomedical, Inc. Research Summary
Elias also spoke about the potential to expand the regulation of this anti-tumor pathway to other cancers, and promising research that reveals additional anti-tumor pathways targeting T-cell stimulation using inducible co-stimulators and ICOSL ligands, as well as the Cluster of Differentiation 28 and B7-1 and B7-2 ligands.
Source: Ocean Biomedical, Inc.
CHI3L1 factor
The company’s research shows that CHI3L1 is a critical regulator of several key pathways leading to cancer. It has the ability to inhibit tumor cell death, inhibit the expression of tumor suppressor P53 and PTEN, and stimulate the B-RAF proto-oncogene.
“Immunotherapy is the future of cancer care, and we are proud to work with Dr. Elias to advance the development of cancer treatments, along with fibrosis treatments, and our global malaria program. We look forward to bringing all of these therapies to patients as Ocean Biomedical moves forward, for long-term shareholder value and the advancement of medical science,” said Suren Ajjarapu, director of Ocean Biomedical.
Ocean Biomedical founder Jake Kurtis gets a new patent for a novel malaria vaccine target
Ocean Biomedical operates as an incubator by partnering with inventors, universities, and research institutes to commercialize discoveries for medical care. Last month, the company went public through a spin-off merger with special purpose acquisition firm Aesther Healthcare Acquisition Corp. The portfolio focuses on the critical areas of oncology, pulmonary fibrosis, and infectious diseases.
Continuing its upward trend after the announcement, shares of Ocean Biomedical traded up 84% on Thursday afternoon.
[ad_2]
Source link